<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914806</url>
  </required_header>
  <id_info>
    <org_study_id>miniNO</org_study_id>
    <nct_id>NCT04914806</nct_id>
  </id_info>
  <brief_title>Infantile NO Replenishment as a New Therapeutic Possibility</brief_title>
  <acronym>miniNO</acronym>
  <official_title>Association Between Premature Birth and Its Comorbidities With NO and the HPG Activation at Minipuberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>URI-NKUA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Case-control study of inhaled Nitric Oxide (iNO) treatment of full-term and preterm infants.&#xD;
      The main objective of this study is to investigate the association between premature birth&#xD;
      and its later comorbidities (neuroendocrine, metabolic, cognitive, etc) with iNO treatment&#xD;
      and the maturation of the HPG axis during minipuberty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preterm infants, inhaled NO (iNO) is routinely used to treat respiratory failure and&#xD;
      pulmonary hypertension, while preclinical studies have shown that it markedly increases NO&#xD;
      concentrations in the brain. Animal and human studies have shown that NO deficiency may&#xD;
      jeopardize the establishment of a mature and functional HPG axis whereas it is also&#xD;
      associated with a series of comorbidities affecting the overall brain development (e.g.&#xD;
      sensory, fertility and cognitive functions). Prematurity has been associated with a series of&#xD;
      non-communicable diseases of major importance in public health, including neurodevelopmental&#xD;
      impairments, metabolic abnormalities (e.g. obesity, type 2 diabetes mellitus, impaired&#xD;
      glucose tolerance) and cardiovascular disease. This study aims to evaluate the associations&#xD;
      between altered minipuberty in preterm infants and the later development of&#xD;
      multi-comorbidities (mental and non-mental disorders), and identify the possible implication&#xD;
      of the NO pathway as a causative mechanism.&#xD;
&#xD;
      Specific objectives :&#xD;
&#xD;
        1. Assess the efficiency of NO replenishment therapy (i.e. role of NO pathway) as a&#xD;
           therapeutic against alterations of minipuberty resulting from preterm birth.&#xD;
&#xD;
        2. Assess the efficiency of NO replenishment therapy (i.e. role of NO pathway) as a&#xD;
           therapeutic against the multi-comorbidities (mental and non-mental disorders) related to&#xD;
           altered minipuberty as a result of preterm birth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gonadotrophin levels</measure>
    <time_frame>up to 9 months of age</time_frame>
    <description>Serial blood levels of gonadotrophins (FSH and LH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body fat and fat-free mass</measure>
    <time_frame>up to 9 months of age</time_frame>
    <description>Serial fat and fat-free mass measurements by air displacement plethysmography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>up to 9 months</time_frame>
    <description>Serial measurements of blood glucose/insulin (HOMA-IR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bayleys scale score</measure>
    <time_frame>at 9 months of age</time_frame>
    <description>The Bayley Scales of Infant and Toddler Development will be used to assess neurodevelopment. Values &lt;85 indicate developmental delay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Otoacoustic emissions</measure>
    <time_frame>up to 9 months</time_frame>
    <description>Serial otoacoustic emissions as a screening test for hearing ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundoscopy</measure>
    <time_frame>up to 9 months</time_frame>
    <description>Ophthalmological follow-up for retina and visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gusto-facial reflex</measure>
    <time_frame>at 3 and 9 months of age</time_frame>
    <description>Assessment of olfaction will be performed using a citrus, vanilla or neutral odor, delivered on a cotton swab. The facial expressions in reaction to the different smells (the gusto-facial reflex) will be monitored while at rest (baseline), and in response to stimuli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin levels</measure>
    <time_frame>up to 9 months</time_frame>
    <description>Serial measurements of serum leptin levels</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prematurity</condition>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Infants treated with iNO (from birth to 1-3 weeks of life) or sequential treatment with iNO and sildenafil (for 1 to 3 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Infants matched to cases (gestational/postnatal age, gender, disease state) and no iNO treatment.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for hormones and metabolic parameters; genetic and epigenetic screening for NO&#xD;
      pathway.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Preterm and full-term infants admitted to the Neonatal Unit due to respiratory distress.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm (GA&lt;37 weeks) or full-term (â‰¥37 weeks of gestation) infants&#xD;
&#xD;
          -  Requiring respiratory support&#xD;
&#xD;
          -  Admitted to Neonatal Care Unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe congenital anomalies&#xD;
&#xD;
          -  Suspected major chromosomal anomalies&#xD;
&#xD;
          -  Infants judged by the physician as nonviable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George P. Chrousos, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>URI-NKUA, Athens, Greece, 11527</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George P. Chrousos, Professor</last_name>
    <phone>+302107795553</phone>
    <email>chrousos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soultana (Tania) Siahanidou, Professor</last_name>
    <phone>+30213 2013 517</phone>
    <email>siahan@med.uoa.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Et Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent Storme, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>URI-NKUA</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>George Chrousos, Professor</last_name>
      <phone>+302107795553</phone>
      <email>chrousos@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tania Siahanidou, Professor</last_name>
      <phone>+302132013517</phone>
      <email>siahan@med.uoa.gr</email>
    </contact_backup>
    <investigator>
      <last_name>George P. Chrousos, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tania Siahanidou, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleni Koniari, Researcher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aikaterini Sarra, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Soultana (Tania) Siahanidou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>preterm birth</keyword>
  <keyword>neurodevelopment</keyword>
  <keyword>cardiometabolic</keyword>
  <keyword>minipuberty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

